JP2019068857A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019068857A5 JP2019068857A5 JP2019019707A JP2019019707A JP2019068857A5 JP 2019068857 A5 JP2019068857 A5 JP 2019068857A5 JP 2019019707 A JP2019019707 A JP 2019019707A JP 2019019707 A JP2019019707 A JP 2019019707A JP 2019068857 A5 JP2019068857 A5 JP 2019068857A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- microglobulin
- acid sequence
- nucleic acid
- human animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 40
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 40
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 29
- 150000007523 nucleic acids Chemical group 0.000 claims 29
- 108091006028 chimera Proteins 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 12
- 230000001105 regulatory Effects 0.000 claims 6
- 229920000665 Exon Polymers 0.000 claims 4
- 241000700159 Rattus Species 0.000 claims 3
- 241000283984 Rodentia Species 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 102000028367 human B2M protein Human genes 0.000 claims 3
- 108091005294 human B2M protein Proteins 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000001161 Embryo, Mammalian Anatomy 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
Claims (30)
- 内在性非ヒトβ２ミクログロブリン遺伝子座において、ヒトβ２ミクログロブリン遺伝子のエクソン２、エクソン３およびエクソン４を含む核酸配列を含む、非ヒト動物であって、該核酸配列が、機能的なヒトまたはキメラヒト／非ヒト動物β２ミクログロブリンアミノ酸配列をコードし、該非ヒト動物が、機能的なヒトまたはキメラヒト／非ヒト動物β２ミクログロブリンポリペプチドを発現する、非ヒト動物。
- 核酸配列が、ヒトβ２ミクログロブリン遺伝子のエクソン２〜エクソン４を含む、請求項１に記載の非ヒト動物。
- 前記機能的なヒトまたはキメラヒト／非ヒト動物β２ミクログロブリンが、ヒトβ２ミクログロブリンタンパク質のアミノ酸２３〜１１９を含む、請求項１または請求項２に記載の非ヒト動物。
- 前記核酸配列がさらに、非ヒト動物β２ミクログロブリン遺伝子のエクソン１を含む、請求項１〜３のいずれか一項に記載の非ヒト動物。
- 前記核酸配列が、内在性非ヒトβ２ミクログロブリン調節エレメントに作動可能に連結している、請求項１〜４のいずれか一項に記載の非ヒト動物。
- 前記非ヒト動物が、内在性非ヒトβ２ミクログロブリン遺伝子座から、機能的な内在性非ヒトβ２ミクログロブリンポリペプチドを発現しない、請求項１〜５のいずれか一項に記載の非ヒト動物。
- 前記非ヒト動物がげっ歯動物である、請求項１〜６のいずれか一項に記載の非ヒト動物。
- 前記非ヒト動物がラットまたはマウスである、請求項１〜７のいずれか一項に記載の非ヒト動物。
- 前記非ヒト動物がマウスであり、該マウスが、内在性β２ミクログロブリン遺伝子座において、（１）マウスβ２ミクログロブリン遺伝子のエクソン１と、ヒトβ２ミクログロブリン遺伝子のエクソン２、エクソン３およびエクソン４とを含み、（２）マウスβ２ミクログロブリン調節エレメントに作動可能に連結しており、かつ、（３）機能的なキメラヒト／非ヒト動物β２ミクログロブリンポリペプチドをコードする、核酸配列を含む、請求項１〜８のいずれか一項に記載の非ヒト動物。
- 機能的なヒトまたはキメラヒト／非ヒト動物β２ミクログロブリンポリペプチドを発現するように、マウスのβ２ミクログロブリン遺伝子座を改変する方法であって、該方法は、内在性の該マウスβ２ミクログロブリン遺伝子座において、マウスβ２ミクログロブリン遺伝子のエクソン２〜４を含む核酸配列を、ヒトβ２ミクログロブリン遺伝子のエクソン２、エクソン３およびエクソン４を含む核酸配列で置き換える工程を含む、方法。
- 前記機能的なヒトまたはキメラヒト／非ヒト動物β２ミクログロブリンポリペプチドをコードする核酸配列が、ヒトβ２ミクログロブリン遺伝子のエクソン２〜エクソン４を含む、請求項１０に記載の方法。
- 改変された前記遺伝子座が、マウスβ２ミクログロブリン遺伝子のエクソン１を保持する、請求項１０または請求項１１に記載の方法。
- 前記マウスが、内在性β２ミクログロブリン遺伝子座から、機能的なマウスβ２ミクログロブリンポリペプチドを発現しない、請求項１０〜１２のいずれか一項に記載の方法。
- 前記置き換えが、単一のＥＳ細胞において行われ、該単一のＥＳ細胞が、マウスを作製するためにマウス胚に導入される、請求項１０〜１３のいずれか一項に記載の方法。
- 機能的なキメラヒト／非ヒト動物β２ミクログロブリンポリペプチドをコードする核酸配列であって、該核酸配列は、非ヒト動物β２ミクログロブリン遺伝子のエクソン１と、ヒトβ２ミクログロブリン遺伝子のエクソン２、エクソン３およびエクソン４とを含む、核酸配列。
- 核酸配列が、ヒトβ２ミクログロブリン遺伝子のエクソン２〜エクソン４を含む、請求項１５に記載の核酸配列。
- 前記機能的なキメラヒト／非ヒト動物β２ミクログロブリンポリペプチドが、ヒトβ２ミクログロブリンタンパク質のアミノ酸２３〜１１９を含む、請求項１５または請求項１６に記載の核酸配列。
- 前記核酸配列がさらに、げっ歯動物β２ミクログロブリン遺伝子のエクソン１を含む、請求項１５〜１７のいずれか一項に記載の核酸配列。
- 前記核酸配列がさらに、ラットβ２ミクログロブリン遺伝子のエクソン１を含む、請求項１５〜１８のいずれか一項に記載の核酸配列。
- 前記核酸配列がさらに、マウスβ２ミクログロブリン遺伝子のエクソン１を含む、請求項１５〜１８のいずれか一項に記載の核酸配列。
- 前記核酸配列が、非ヒト動物β２ミクログロブリン調節エレメントに作動可能に連結している、請求項１５〜２０のいずれか一項に記載の核酸配列。
- 前記核酸配列が、げっ歯動物β２ミクログロブリン調節エレメントに作動可能に連結している、請求項１５〜２１のいずれか一項に記載の核酸配列。
- 前記核酸配列が、ラットβ２ミクログロブリン調節エレメントに作動可能に連結している、請求項１５〜２２のいずれか一項に記載の核酸配列。
- 前記核酸配列が、マウスβ２ミクログロブリン調節エレメントに作動可能に連結している、請求項１５〜２２のいずれか一項に記載の核酸配列。
- キメラヒト／非ヒトＭＨＣ Ｉタンパク質に非共有結合したヒトβ２ミクログロブリンタンパク質のアミノ酸２３〜１１９を含む、機能的なキメラヒト／非ヒト動物β２ミクログロブリンポリペプチド。
- 請求項１５〜２４のいずれか一項に記載の核酸配列を含み、かつ／または、請求項２５に記載のキメラヒト／非ヒト動物β２ミクログロブリンポリペプチドを発現する、単離された細胞。
- 前記細胞が胚性幹（ＥＳ）細胞である、請求項２６に記載の単離された細胞。
- 前記細胞がその表面上に前記キメラヒト／非ヒト動物β２ミクログロブリンポリペプチドを発現する、請求項２６に記載の単離された細胞。
- 請求項２６〜２８のいずれか一項に記載の単離された細胞を含む、ｉｎ ｖｉｔｒｏ組成物。
- 前記単離された細胞が、ＭＨＣ Ｉタンパク質に非共有結合した前記ヒト／非ヒト動物β２ミクログロブリンポリペプチドを発現し、前記細胞が、ヒトまたは非ヒトＴ細胞と複合体化される、請求項２９に記載のｉｎ ｖｉｔｒｏ組成物。
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552582P | 2011-10-28 | 2011-10-28 | |
| US201161552587P | 2011-10-28 | 2011-10-28 | |
| US61/552,582 | 2011-10-28 | ||
| US61/552,587 | 2011-10-28 | ||
| US201261700908P | 2012-09-14 | 2012-09-14 | |
| US61/700,908 | 2012-09-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017109327A Division JP6574457B2 (ja) | 2011-10-28 | 2017-06-01 | 遺伝子改変された主要組織適合複合体マウス |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020081774A Division JP2020146041A (ja) | 2011-10-28 | 2020-05-07 | 遺伝子改変された主要組織適合複合体マウス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019068857A JP2019068857A (ja) | 2019-05-09 |
| JP2019068857A5 true JP2019068857A5 (ja) | 2019-12-19 |
| JP6866409B2 JP6866409B2 (ja) | 2021-04-28 |
Family
ID=47178940
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014539029A Active JP6154391B2 (ja) | 2011-10-28 | 2012-10-26 | 遺伝子改変された主要組織適合複合体マウス |
| JP2017109327A Active JP6574457B2 (ja) | 2011-10-28 | 2017-06-01 | 遺伝子改変された主要組織適合複合体マウス |
| JP2019019707A Active JP6866409B2 (ja) | 2011-10-28 | 2019-02-06 | 遺伝子改変された主要組織適合複合体マウス |
| JP2020081774A Withdrawn JP2020146041A (ja) | 2011-10-28 | 2020-05-07 | 遺伝子改変された主要組織適合複合体マウス |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014539029A Active JP6154391B2 (ja) | 2011-10-28 | 2012-10-26 | 遺伝子改変された主要組織適合複合体マウス |
| JP2017109327A Active JP6574457B2 (ja) | 2011-10-28 | 2017-06-01 | 遺伝子改変された主要組織適合複合体マウス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020081774A Withdrawn JP2020146041A (ja) | 2011-10-28 | 2020-05-07 | 遺伝子改変された主要組織適合複合体マウス |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US9615550B2 (ja) |
| EP (4) | EP4311833A3 (ja) |
| JP (4) | JP6154391B2 (ja) |
| KR (3) | KR102074145B1 (ja) |
| CN (3) | CN107254480B (ja) |
| AU (3) | AU2012324016C1 (ja) |
| BR (1) | BR112014009259A2 (ja) |
| CA (2) | CA2850387A1 (ja) |
| CY (2) | CY1119657T1 (ja) |
| DK (2) | DK3262932T3 (ja) |
| ES (3) | ES2962287T3 (ja) |
| HK (2) | HK1200272A1 (ja) |
| HR (2) | HRP20171761T1 (ja) |
| HU (2) | HUE045879T2 (ja) |
| IL (3) | IL232097A (ja) |
| LT (2) | LT3262932T (ja) |
| MX (2) | MX355725B (ja) |
| MY (2) | MY178723A (ja) |
| NZ (1) | NZ734532A (ja) |
| PL (2) | PL3262932T3 (ja) |
| PT (2) | PT3262932T (ja) |
| RS (2) | RS56656B1 (ja) |
| SG (2) | SG11201400933VA (ja) |
| SI (2) | SI3262932T1 (ja) |
| WO (1) | WO2013063346A1 (ja) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| EP2818478B1 (en) | 2011-10-28 | 2017-02-01 | Regeneron Pharmaceuticals, Inc. | Humanized IL-6 and IL-6 receptor |
| EP2958938B1 (en) | 2013-02-20 | 2019-04-17 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
| SI2958937T1 (sl) * | 2013-02-22 | 2018-12-31 | Regeneron Pharmaceuticals, Inc. | Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| CN105188358B (zh) * | 2013-03-11 | 2018-01-26 | 瑞泽恩制药公司 | 表达嵌合的主要组织相容性复合物(mhc)i类分子的转基因小鼠 |
| IL297607B2 (en) | 2013-09-23 | 2024-01-01 | Regeneron Pharma | Non-human animals with a humanized gene for SIGNAL-REGULATORY PROTEIN |
| KR102376041B1 (ko) | 2013-10-15 | 2022-03-18 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 il-15 동물 |
| ES2874501T3 (es) * | 2013-10-18 | 2021-11-05 | Taiho Pharmaceutical Co Ltd | Animal no humano que expresa HLA de clase I |
| SG11201604886WA (en) | 2014-04-08 | 2016-07-28 | Regeneron Pharma | Non-human animals having humanized fc-gamma receptors |
| AU2015256299C1 (en) | 2014-05-05 | 2022-01-06 | Regeneron Pharmaceuticals, Inc. | Humanized C5 and C3 animals |
| NO2785538T3 (ja) | 2014-05-07 | 2018-08-04 | ||
| EP3157956B1 (en) | 2014-06-19 | 2020-02-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized programmed cell death 1 gene |
| AU2015317370A1 (en) | 2014-09-19 | 2017-03-23 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
| LT3689140T (lt) | 2014-11-24 | 2022-08-25 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, išskyrus žmones, ekspresuojantys humanizuotą cd3 kompleksą |
| FI3850946T3 (fi) | 2014-12-05 | 2023-12-28 | Regeneron Pharma | Ei-ihmiseläimiä, joilla on humanisoitu erilaistumisklusterin 47 geeni |
| CN107257624B (zh) * | 2014-12-09 | 2021-07-13 | 瑞泽恩制药公司 | 具有人源化分化簇274基因的非人动物 |
| JP6830437B2 (ja) * | 2014-12-10 | 2021-02-17 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 疾患を処置するための遺伝子改変された細胞、組織および臓器 |
| AU2016246698B2 (en) | 2015-04-06 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Humanized T cell mediated immune responses in non-human animals |
| RU2020124128A (ru) * | 2015-04-13 | 2020-09-22 | Ридженерон Фармасьютикалз, Инк. | Гуманизированные мыши с нокином sirpa-il15 и способы их использования |
| MX2018005389A (es) | 2015-11-20 | 2018-09-05 | Regeneron Pharma | Animales no humanos que tienen un gen 3 de activacion linfocitaria humanizado. |
| CN109068621B (zh) | 2016-02-29 | 2021-07-20 | 再生元制药公司 | 具有人源化的tmprss基因的啮齿类动物 |
| CN116458475A (zh) | 2016-06-03 | 2023-07-21 | 瑞泽恩制药公司 | 表达外源末端脱氧核苷酸转移酶的非人动物 |
| CN109456942A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技（上海）有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
| SI3687287T1 (sl) | 2017-09-29 | 2023-11-30 | Regeneron Pharmaceuticals, Inc. | Glodavci, ki izražajo humaniziran kompleks C1Q |
| JP7361031B2 (ja) | 2017-11-30 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物 |
| WO2019190922A1 (en) | 2018-03-24 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
| KR20210004994A (ko) | 2018-03-26 | 2021-01-13 | 리제너론 파마슈티칼스 인코포레이티드 | 치료제를 시험하기 위한 인간화된 설치류 |
| KR20210031868A (ko) | 2018-07-16 | 2021-03-23 | 리제너론 파마슈티칼스 인코포레이티드 | Ditra 질환의 비인간 동물 모델 및 이의 용도 |
| WO2020206139A1 (en) | 2019-04-04 | 2020-10-08 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized coagulation factor 12 locus |
| JP2022534867A (ja) | 2019-06-04 | 2022-08-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ベータスリップ変異を有するヒト化ｔｔｒ遺伝子座を含む非ヒト動物と使用方法 |
| BR112021022722A2 (pt) | 2019-06-07 | 2022-01-04 | Regeneron Pharma | Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente |
| US20230072216A1 (en) * | 2020-01-10 | 2023-03-09 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric mhc protein complex |
| WO2022133155A1 (en) * | 2020-12-16 | 2022-06-23 | Xenotherapeutics, Inc. | Humanization of beta2-microglobulin in porcine genome resulting in functional expression of human βeta2-microglobulin within donor cells, tissues, or organs |
| KR20230147048A (ko) | 2020-12-16 | 2023-10-20 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 Fc 알파 수용체를 발현하는 마우스 |
| BR112023018874A2 (pt) | 2021-03-31 | 2023-10-03 | Regeneron Pharma | Camundongos geneticamente modificados compreendendo componentes do sistema imunológico celular humanizado com diversidade melhorada do repertório de tcrb |
| WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
| WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| WO2024064860A1 (en) | 2022-09-22 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice expressing components of human cellular immune system |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| EP0437576B1 (en) | 1989-07-25 | 2002-07-03 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
| AU2661692A (en) | 1991-09-19 | 1993-04-27 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
| EP0663952A4 (en) | 1992-09-11 | 1997-06-11 | Univ California | TRANSGENIC NON-HUMAN ANIMALS WITH TARGETED INTERRUPTED TRANSDUCTION GENES IN LYMPHOCYTES. |
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| GB9315303D0 (en) | 1993-07-23 | 1993-09-08 | Zeneca Ltd | Polypeptide |
| US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
| US6002066A (en) | 1996-01-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | H2-M modified transgenic mice |
| WO1997032603A1 (en) | 1996-03-05 | 1997-09-12 | The Scripps Research Institute | Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens |
| ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
| AU741130B2 (en) | 1997-09-16 | 2001-11-22 | Oregon Health Sciences University | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
| US6372955B1 (en) | 1998-02-17 | 2002-04-16 | Ortho Mcneil Pharmaceutical, Inc. | Methods for Producing B cells and antibodies from H2-O modified transgenic mice |
| AU1023401A (en) * | 1999-10-12 | 2001-04-23 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU2002222610A1 (en) | 2000-12-13 | 2002-06-24 | Sumitomo Pharmaceuticals Company, Limited | Transgenic animal expressing hla-a24 and utilization thereof |
| AU2002246733B2 (en) | 2000-12-19 | 2007-09-20 | Altor Bioscience Corporation | Transgenic animals comprising a humanized immune system |
| FR2827302B1 (fr) * | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
| US8895020B2 (en) | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
| US7179645B2 (en) * | 2002-09-24 | 2007-02-20 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
| US7663017B2 (en) | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
| JP4857450B2 (ja) | 2004-03-09 | 2012-01-18 | 財団法人名古屋産業科学研究所 | ヒト関節リウマチの病態を再現するトランスジェニック非ヒト哺乳動物 |
| PT1802193E (pt) | 2004-10-19 | 2014-06-23 | Regeneron Pharma | Método para gerar um murganho homozigótico para uma modificação genética |
| JP4830139B2 (ja) * | 2006-03-10 | 2011-12-07 | 学校法人明治大学 | クローン胚の作製方法 |
| NZ547859A (en) * | 2006-06-09 | 2009-05-31 | Dec Int Nz Ltd | Treatment method and composition for mastitis |
| EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| EP1878798A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies |
| CN101986783A (zh) * | 2007-04-23 | 2011-03-16 | 先灵公司 | 抗mdl-1抗体 |
| US20090271884A1 (en) | 2008-03-07 | 2009-10-29 | Regeneron Pharmaceuticals, Inc. | ES Cell-Derived Mice From Diploid Host Embryo Injection |
| US20090328240A1 (en) | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
| EP2153845A1 (en) * | 2008-08-13 | 2010-02-17 | Julius-Maximilians-Universität Würzburg | Endoglin peptides, vaccines and methods for preparing the same |
| DK3241435T3 (da) * | 2009-07-08 | 2021-08-23 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
| US9557323B2 (en) | 2010-09-24 | 2017-01-31 | The United States Of America As Represented By The Secretary Of The Navy | Humanized transgenic mouse model |
| EP2958938B1 (en) | 2013-02-20 | 2019-04-17 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
| SI2958937T1 (sl) | 2013-02-22 | 2018-12-31 | Regeneron Pharmaceuticals, Inc. | Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| AU2016246698B2 (en) | 2015-04-06 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Humanized T cell mediated immune responses in non-human animals |
-
2012
- 2012-10-26 EP EP23193595.8A patent/EP4311833A3/en active Pending
- 2012-10-26 ES ES19167619T patent/ES2962287T3/es active Active
- 2012-10-26 CA CA2850387A patent/CA2850387A1/en active Pending
- 2012-10-26 AU AU2012324016A patent/AU2012324016C1/en active Active
- 2012-10-26 CN CN201710347715.8A patent/CN107254480B/zh active Active
- 2012-10-26 KR KR1020187033187A patent/KR102074145B1/ko active IP Right Grant
- 2012-10-26 SG SG11201400933VA patent/SG11201400933VA/en unknown
- 2012-10-26 PL PL17184955T patent/PL3262932T3/pl unknown
- 2012-10-26 LT LTEP17184955.7T patent/LT3262932T/lt unknown
- 2012-10-26 SI SI201231650T patent/SI3262932T1/sl unknown
- 2012-10-26 US US13/661,159 patent/US9615550B2/en active Active
- 2012-10-26 PL PL12787255T patent/PL2770821T3/pl unknown
- 2012-10-26 PT PT17184955T patent/PT3262932T/pt unknown
- 2012-10-26 CN CN201280060540.8A patent/CN104039132B9/zh active Active
- 2012-10-26 CA CA3074400A patent/CA3074400A1/en active Pending
- 2012-10-26 KR KR1020207002887A patent/KR102295746B1/ko active IP Right Grant
- 2012-10-26 RS RS20171195A patent/RS56656B1/sr unknown
- 2012-10-26 SI SI201231136T patent/SI2770821T1/en unknown
- 2012-10-26 CN CN202110831383.7A patent/CN113564188A/zh active Pending
- 2012-10-26 WO PCT/US2012/062042 patent/WO2013063346A1/en active Application Filing
- 2012-10-26 JP JP2014539029A patent/JP6154391B2/ja active Active
- 2012-10-26 MY MYPI2017703836A patent/MY178723A/en unknown
- 2012-10-26 MX MX2014004895A patent/MX355725B/es active IP Right Grant
- 2012-10-26 EP EP19167619.6A patent/EP3563680B1/en active Active
- 2012-10-26 BR BR112014009259-1A patent/BR112014009259A2/pt not_active Application Discontinuation
- 2012-10-26 LT LTEP12787255.4T patent/LT2770821T/lt unknown
- 2012-10-26 SG SG10201603188SA patent/SG10201603188SA/en unknown
- 2012-10-26 PT PT127872554T patent/PT2770821T/pt unknown
- 2012-10-26 RS RS20190998A patent/RS59082B1/sr unknown
- 2012-10-26 MX MX2020010763A patent/MX2020010763A/es unknown
- 2012-10-26 MY MYPI2014000784A patent/MY164836A/en unknown
- 2012-10-26 DK DK17184955.7T patent/DK3262932T3/da active
- 2012-10-26 KR KR1020147014476A patent/KR101921126B1/ko active IP Right Grant
- 2012-10-26 ES ES12787255.4T patent/ES2651517T3/es active Active
- 2012-10-26 EP EP17184955.7A patent/EP3262932B1/en active Active
- 2012-10-26 HU HUE17184955A patent/HUE045879T2/hu unknown
- 2012-10-26 NZ NZ734532A patent/NZ734532A/en unknown
- 2012-10-26 DK DK12787255.4T patent/DK2770821T3/da active
- 2012-10-26 HU HUE12787255A patent/HUE035652T2/en unknown
- 2012-10-26 ES ES17184955T patent/ES2741649T3/es active Active
- 2012-10-26 EP EP12787255.4A patent/EP2770821B1/en active Active
-
2014
- 2014-04-13 IL IL232097A patent/IL232097A/en active IP Right Grant
-
2015
- 2015-01-29 HK HK15101011.6A patent/HK1200272A1/xx unknown
-
2016
- 2016-04-27 AU AU2016202688A patent/AU2016202688B2/en active Active
-
2017
- 2017-02-22 US US15/439,828 patent/US10869466B2/en active Active
- 2017-04-30 IL IL252022A patent/IL252022A0/en active IP Right Grant
- 2017-06-01 JP JP2017109327A patent/JP6574457B2/ja active Active
- 2017-11-15 HR HRP20171761TT patent/HRP20171761T1/hr unknown
- 2017-11-22 CY CY20171101223T patent/CY1119657T1/el unknown
- 2017-12-22 AU AU2017279797A patent/AU2017279797C1/en active Active
-
2018
- 2018-06-29 HK HK18108466.8A patent/HK1249712B/zh unknown
- 2018-08-20 IL IL26123918A patent/IL261239B/en active IP Right Grant
-
2019
- 2019-02-06 JP JP2019019707A patent/JP6866409B2/ja active Active
- 2019-08-06 HR HRP20191420 patent/HRP20191420T1/hr unknown
- 2019-08-07 CY CY20191100840T patent/CY1121869T1/el unknown
-
2020
- 2020-05-07 JP JP2020081774A patent/JP2020146041A/ja not_active Withdrawn
- 2020-08-12 US US16/991,283 patent/US20200375160A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019068857A5 (ja) | ||
| Ristevski | Making better transgenic models: conditional, temporal, and spatial approaches | |
| US10975390B2 (en) | Targeted modification of rat genome | |
| JP7088992B2 (ja) | ヒト化ｓｉｒｐａ－ｉｌ１５ノックインマウス及びその使用方法 | |
| JP2017505127A5 (ja) | ||
| JP2018126170A5 (ja) | ||
| Zhang et al. | Inactivation of the myogenic bHLH gene MRF4 results in up-regulation of myogenin and rib anomalies. | |
| Li et al. | Requirement for serum response factor for skeletal muscle growth and maturation revealed by tissue-specific gene deletion in mice | |
| HRP20202034T1 (hr) | Neljudske životinje s genom za humanizirani diferencijacijski biljeg cd274 | |
| Gonen et al. | Normal levels of Sox9 expression in the developing mouse testis depend on the TES/TESCO enhancer, but this does not act alone | |
| Spear et al. | Transcriptional control in the mammalian liver: liver development, perinatal repression, and zonal gene regulation | |
| JP2017514496A5 (ja) | ||
| JP2019022518A5 (ja) | ||
| Liu et al. | Ablation of cDC2 development by triple mutations within the Zeb2 enhancer | |
| RU2016123708A (ru) | Отличные от человека животные, содержащие гуманизированный ген фактора активации в-клеток | |
| JP2017514501A5 (ja) | ||
| WO2015077072A4 (en) | Non-human animals having a humanized a proliferation-inducing ligand gene | |
| DK0620849T3 (da) | Transgene dyremodeller for Alzheimer's sygdom | |
| JP2021502085A5 (ja) | ||
| JP2019506897A5 (ja) | ||
| Li et al. | A transgenic zebrafish model for monitoring xbp1 splicing and endoplasmic reticulum stress in vivo | |
| Oura et al. | KCTD19 and its associated protein ZFP541 are independently essential for meiosis in male mice | |
| Hendrickx et al. | Conditional mouse models support the role of SLC39A14 (ZIP14) in hyperostosis cranialis interna and in bone homeostasis | |
| Cheng et al. | Generation and characterization of transgenic mice expressing mouse Ins1 promoter for pancreatic β-cell-specific gene overexpression and knockout | |
| JP2021526815A (ja) | 進行性骨化性線維異形成症のげっ歯類モデル |